



The EU model of increasing access to high quality pharmaceutical treatments while keeping government spending in check

**International Health Forum
APMGR
Bucharest
15th Sep 2015**



**Christoph Schwierz, Policy Analyst
Sustainability of public finances
DG Economic and Financial Affairs (DG ECFIN), European Commission**



Efficiency of
healthcare systems as a key lever to ensure
sustainability of national budgets
whilst
underlining the importance of ensuring
broad
access to affordable and high-quality
health care.

The Juncker Commission's top priority is to get Europe growing again and to increase the number of jobs without creating new debt.

Deterioration in fiscal positions and increases in government debt since 2008



Fiscal responsibility




Projected costs of population ageing in the EU



AGE-RELATED PUBLIC EXPENDITURES

2013

2060



MANAGING THE CHANGE

Recent sustainability-enhancing reforms, in particular of pension systems but also of health systems, help to keep the projected increases in age-related public expenditure over the long-term in check.

As healthcare is mostly publicly financed, this investment comes at a significant cost to the public.




Structural reforms




- Not only how much money is spent, but also how it is spent

A closer look at relative efficiency in EU healthcare systems


Member States achieve very different levels of health outcomes for the same money spent. All Member States could have better results without spending more and by increasing expenditure efficiency.



* According to Heijink R. et al, adjusted for the impact of lifestyle differences, such as smoking and alcohol consumption (2015)




- Questionable innovation



- Only one out of the 20 innovative medicines put on the market in Germany have therapeutical value-added.

Increasing value for money in health spending

- Measures introduced in the last two decades aimed at
 - improving value for money and
 - slowing down the growth of health spending
- will have to be intensified in the immediate future to achieve the needed consolidation of public finances in Europe



- Policies promoting the use of generic medicines are often at the forefront in the attempt to increase the value for medicinal products





- 'Investing in health': Health is a value in itself and a precondition for economic prosperity.
- The revised Stability and Growth Pact makes room for Member States to invest in health
- European Fund for Strategic Investments
- Some actions to support the pharmaceutical sector
 - Identifying priorities for innovation
 - HTA
 - Fostering Public-Private Cooperation

So, what is the EU Model?



STRUCTURAL
REFORMS



INVESTMENT

FISCAL
RESPONSIBILITY

How could the EU contribute to these challenges?

- Joint HTA
- Joint procurement
- Fostering innovation in Pricing & Reimbursement

"We need more Europe in our Union. We need more Union in our Union."

